GlaxoSmithKline Pharmaceuticals (GSK Pharma) just had a pretty solid quarter. Their stock went up more than 3%, closing at ₹2,879.70 after they dropped their Q4 results for FY25. And honestly, the numbers speak for themselves. Their standalone net profit shot up by almost 35% year-over-year, landing at ₹260.14 crore. That jump came mostly because they’ve gotten better at managing their operations and cut down on a lot of costs. Revenue also climbed a bit—around 6%—reaching ₹966.08 crore.
They’re also giving out a final dividend of ₹42 per share for the year, though that’s still waiting on shareholder approval at their upcoming 100th Annual General Meeting. So yeah, if you’re a shareholder, that’s something to look forward to.
What’s Behind the Numbers? Big Cuts + Strong Products
Here’s what really stood out. They didn’t just earn more—they also spent less. GSK’s total expenses dropped by over 3%, which helped boost profits big time. Material costs were slashed by nearly 44%, and employee expenses went down more than 11%. That’s not something you see often, and it clearly made a difference.
Here are some key numbers from the report:
-
Q4 Net Profit: ₹260.14 crore (up 34.7% YoY)
-
Revenue: ₹966.08 crore (up 6.06% YoY)
-
Profit Before Tax: ₹354.90 crore (up 32.08% YoY)
-
Full-Year Net Profit (FY25): ₹919.06 crore (up 57.19% YoY)
-
FY25 Revenue: ₹3,723.49 crore (up 9.28% YoY)
A lot of the growth came from strong performance by core brands like Augmentin, Calpol, Ceftum, T-Bact, and Trelegy. And let’s not forget Shingrix, the vaccine for shingles. It’s been gaining more attention, especially as the company focuses more on adult vaccines in India.
Looking Ahead: New Drugs Coming, Long-Term Looks Good
According to GSK Pharma’s MD, Bhushan Akshikar, the company’s doing well thanks to its diverse mix of general meds, specialty treatments, and vaccines. But they’re not stopping there. Two new drugs are in the pipeline that could change the game in cancer care:
-
Zejula (Niraparib): This one’s a PARP inhibitor meant for ovarian cancer.
-
Jemperli (Dostarlimab): An immunotherapy aimed at second-line treatment for endometrial cancer.
So while the revenue growth this quarter wasn’t massive, the company clearly has long-term potential. Cutting down on raw material costs and employee spending while still pushing ahead with new drugs is a good sign for what’s ahead. It feels like they’re building something sustainable.
Note: This article is just for general info. It’s not investment advice. Always talk to a proper financial advisor—preferably one registered with SEBI—before you make any big decisions. And yeah, the opinions shared here are just that—opinions. Not the official stance of Jobaaj Media or any of its people
